[go: up one dir, main page]

WO2002015874A2 - Compositions pour soins personnels contenant un polymere filmogene anionique et un polymere elastomere adhesif - Google Patents

Compositions pour soins personnels contenant un polymere filmogene anionique et un polymere elastomere adhesif Download PDF

Info

Publication number
WO2002015874A2
WO2002015874A2 PCT/US2001/026234 US0126234W WO0215874A2 WO 2002015874 A2 WO2002015874 A2 WO 2002015874A2 US 0126234 W US0126234 W US 0126234W WO 0215874 A2 WO0215874 A2 WO 0215874A2
Authority
WO
WIPO (PCT)
Prior art keywords
skin
composition
polymer
styrene
composition according
Prior art date
Application number
PCT/US2001/026234
Other languages
English (en)
Other versions
WO2002015874A3 (fr
WO2002015874A8 (fr
Inventor
Ali Abdelaziz Alwattari
Original Assignee
The Procter & Gamble Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Procter & Gamble Company filed Critical The Procter & Gamble Company
Priority to AU2001286624A priority Critical patent/AU2001286624A1/en
Publication of WO2002015874A2 publication Critical patent/WO2002015874A2/fr
Publication of WO2002015874A3 publication Critical patent/WO2002015874A3/fr
Publication of WO2002015874A8 publication Critical patent/WO2002015874A8/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0212—Face masks
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/046—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
    • A61K8/8105—Compositions of homopolymers or copolymers of unsaturated aliphatic hydrocarbons having only one carbon-to-carbon double bond; Compositions of derivatives of such polymers
    • A61K8/8117—Homopolymers or copolymers of aromatic olefines, e.g. polystyrene; Compositions of derivatives of such polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
    • A61Q1/02—Preparations containing skin colorants, e.g. pigments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
    • A61Q1/02—Preparations containing skin colorants, e.g. pigments
    • A61Q1/04—Preparations containing skin colorants, e.g. pigments for lips
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
    • A61Q1/02—Preparations containing skin colorants, e.g. pigments
    • A61Q1/10—Preparations containing skin colorants, e.g. pigments for eyes, e.g. eyeliner, mascara
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/06—Preparations for styling the hair, e.g. by temporary shaping or colouring

Definitions

  • the present invention relates to topical personal care compositions and methods of use thereof.
  • the compositions contain polymers, particularly anionic film-forming polymers in combination with an adhesive elastomeric polymer.
  • Such compositions are useful for modifying the appearance of skin and/or hair, especially for regulating visible and/or tactile discontinuities in skin associated, e.g., with skin aging.
  • Extrinsic factors include ultraviolet radiation (e.g., from sun exposure), environmental pollution, wind, heat, low humidity, harsh surfactants, abrasives, and the like.
  • Intrinsic factors include chronological aging and other biochemical changes from within the skin or hair follicle. Whether extrinsic or intrinsic, these factors result in visible signs of skin aging and environmental damage, such as wrinkling and other forms of roughness (including increased pore size, flaking and skin lines), and other histological changes associated with skin aging or damage.
  • skin wrinkles are a reminder of the disappearance of youth. As a result, the elimination of wrinkles has become a booming business in youth-conscious societies. Treatments range from cosmetic creams and moisturizers to various forms of cosmetic surgery.
  • Extrinsic or intrinsic factors may result in the thinning and general degradation of the skin. For example, as the skin naturally ages, there is a reduction in the cells and blood vessels that supply the skin. There is also a flattening of the dermal-epidermal junction which results in weaker mechanical resistance of this junction. See, for example, Oikarinen, "The Aging of Skin: Chronoaging Versus Photoaging,” Photodermatol. Photoimmunol. Photomed., vol. 7, pp. 3-4, 1990, which is incorporated by reference herein in its entirety.
  • a large number of skin care actives are known in the art and used to improve the health and/or physical appearance of the skin.
  • salicylic acid and benzoyl peroxide are used in skin care compositions to treat acne.
  • Retinol and other retinoids are known for use in skin care compositions to reduce signs of aging skin.
  • Products directed to using stress (for example, created by a film on the skin) to smooth facial wrinkles currently exist on the marketplace.
  • a wrinkle-smoothing product which contains the anionic polymers sodium dextran sulphate and bovine serum albumin.
  • Products such as this do provide a limited reduction of the appearance of wrinkles when applied to the skin.
  • some of these products are generally brittle, glassy, and/or water-sensitive when applied to the surface of the skin. Due to these properties, as soon as the consumer moves their facial muscles (such as to blink or smile), the product fractures. The fracturing can cause many disadvantages, including loss of the wrinkle reduction benefit, and often also causes a highly undesirable visible whiteness or other negative aesthetic.
  • compositions which improve the physical appearance of the skin and/or hair, which are effective in providing an immediate visually perceived benefit in the physical appearance of skin and/or hair, for example, without fracturing or peeling from the skin.
  • the present invention relates to a composition containing from about 0.1% to about 60%, by weight of the composition of an anionic, film-forming polymer having a Tg of greater than 25 °C and a negative charge density of at least one negative charge per two repeating polymer units; from about 0.1% to about 70%, by weight of the composition, of an adhesive elastomeric polymer having a Tg of less than 40°C; and a dermatologically acceptable carrier.
  • the present invention also relates to methods of using such compositions to modify the appearance of skin and/or hair.
  • Said methods generally contain the step of topically applying (either together or in sequence) a safe and effective amount of the individual elements of the composition to the skin and/or hair of a mammal needing such treatment.
  • the present invention also relates to methods of using such compositions to style hair, especially human facial hair (eyelashes, eyebrows).
  • Such methods generally contain the step of topically applying to the hair of a mammal in need of treatment, a safe and effective amount of such compositions.
  • the present invention also relates to a personal care kit useful for modifying the appearance of skin or hair containing an anionic film-forming polymer having a Tg greater than 25°C and an adhesive elastomeric polymer having a Tg of less than 40°C.
  • compositions of the present invention can comprise, consist essentially of, or consist of, the components of the present invention as well as other ingredients described herein.
  • consisting essentially of means that the composition or component may include additional ingredients, but only if the additional ingredients do not materially alter the basic and novel characteristics of the claimed compositions or methods.
  • keratinous tissue refers to keratin-containing layers disposed as the outermost protective covering of mammals (e.g., humans, dogs, cats, etc.) which includes, but is not limited to, skin, lips, hair, toenails, fingernails, cuticles, hooves, etc.
  • skin-acceptable means that the compositions or components thereof so described are suitable for use in contact with mammalian keratinous tissue without undue toxicity, incompatibility, instability, allergic response, and the like.
  • safe and effective amount means an amount of a compound or composition sufficient to significantly induce a positive benefit, preferably a positive keratinous tissue appearance or feel benefit, or positive hair appearance or feel benefit, including independently or in combinations the benefits disclosed herein, but low enough to avoid serious side effects, i.e., to provide a reasonable benefit to risk ratio, within the scope of sound judgment of the skilled artisan.
  • sagging means the laxity, slackness, or the like condition of skin that occurs as a result of loss of, damage to, alterations to, and/or abnormalities in dermal elastin.
  • smoothing and softening as used herein mean altering the surface of the keratinous tissue such that its tactile feel is improved.
  • “Signs of skin aging” include, but are not limited to, all outward visibly and tactilely perceptible manifestations as well as any other macro or micro effects due to skin aging. Such signs may be induced or caused by intrinsic factors or extrinsic factors, e.g., chronological aging and/or environmental damage.
  • compositions containing a combination of an anionic film-forming polymer having a Tg of greater than 25°C and an adhesive elastomeric polymer having a Tg of less than 40°C provide substantially immediate visual benefits in regulating skin condition and styling hair previously unrecognized in the art of which the present inventors are aware.
  • topical applications of an anionic film-forming polymer and an adhesive elastomeric polymer provide controlled delivery of physical stress on the skin or hair while simultaneously accomplishing adhesion and flexibility such that the effect is both acute and sustained, for example, over time, such as over the course of the daytime (8 hours).
  • topical applications of the anionic film-forming polymer and adhesive elastomeric polymer can provide a texture and firming effect, while when applied to hair, the effect is a styling advantage (e.g. smoothing hair, curling eyelashes).
  • the effect of applying anionic film-forming polymer and adhesive polymer to the skin can work for virtually all visible skin texture discontinuities (e.g. wrinkles, fine lines, under eye bags and dark circles, sagging skin, scars/marks, dimples, pores, stretch marks, roughness, skin surface, frown lines, expression lines, rhytides, blemishes, photodamage, crevices, and unevenness).
  • the adhesive elastomeric polymer protects the anionic film- forming polymer film from fracturing or otherwise breaking, and adheres the anionic polymer film to the skin or hair. It is also believed that the texture reduction (e.g. wrinkle smoothing and/or hair styling effect is a result of the anionic film-forming polymer film coating the skin or hair and the physical stress creation caused by the drying of the polymer mixture.
  • the compositions herein are applied to the skin and/or hair and allowed to dry.
  • stress is created on the skin, causing the wrinkled skin (or other discontinuity) to be pulled flat and thereby appear diminished.
  • stress is created on the hair shaft causing a curling or styling effect.
  • the effect on hair can, for example, result in the curling of eyelashes, especially when applied as part of a mascara cosmetic application.
  • compositions of the present invention are also useful for physically regulating the condition of skin and especially for regulating keratinous tissue condition.
  • Regulation of skin condition namely mammalian and in particular human skin condition, is often required due to conditions which may be induced or caused by factors internal ' and/or external to the body. Examples include, environmental damage, radiation exposure (including ultraviolet radiation), chronological aging, menopausal status (e.g., post-menopausal changes in skin), stress, diseases, etc.
  • regulating skin condition includes prophylactically regulating and/or therapeutically regulating skin condition, and may involve one or more of the following benefits: thickening of skin (i.e., building the epidermis and/or dermis and/or sub-dermal (e.g., subcutaneous fat or muscle) layers of the skin and where applicable the keratinous layers of the nail and hair shaft) to reduce skin atrophy, increasing the convolution of the dermal-epidermal border (also known as the rete ridges), preventing loss of skin elasticity (loss, damage and/or inactivation of functional skin elastin) such as elastosis, sagging, loss of skin recoil from deformation; non-melanin skin discoloration such as under eye circles, blotching (e.g., uneven red coloration due to, e.g., rosacea) (hereinafter referred to as "red blotchiness”), sallowness (pale color), discoloration caused by telan
  • prophylactically regulating skin condition includes delaying, minimizing and/or preventing visible and/or tactile discontinuities in skin (e.g., texture irregularities in the skin which may be detected visually or by feel).
  • therapeutically regulating skin condition includes ameliorating, e.g., diminishing, minimizing and/or effacing, discontinuities in skin.
  • compositions of the present invention are also useful for improving skin appearance and/or feel.
  • compositions of the present invention are useful for regulating the appearance of skin condition by providing an immediate visual improvement in skin appearance following application of the composition to the skin.
  • the compositions of the present invention are also useful for styling hair.
  • the compositions of the present invention are useful for curling hair, especially eyelashes.
  • compositions of the present invention contain an anionic film-forming polymer having a Tg of greater than 25°C, an adhesive elastomeric polymer having a Tg of less than 40°C, and a dermatologically acceptable carrier.
  • the compositions herein may also mclude a wide variety of other ingredients.
  • the topical compositions of the present invention include from about 0.1% to about 70%, preferably from about 1% to about 50%, more preferably from about 3% to about 40%, even more preferably from about 5% to about 25%, by weight of the composition, of an anionic, film- forming polymer having a Tg of greater than 25 °C and having a negative charge density of at least one negative charge per every two repeating units of polymer.
  • the term "glass transition” or "Tg” is a known term of art in polymer science used to describe the temperature at which a polymer or portion thereof undergoes a transition from a solid or brittle material to a liquid or rubber-like material. Glass transition temperatures can be measured using standard techniques that are well known to the polymer scientist of ordinary skill in the art.
  • differential scanning calorimetry also known as DSC.
  • a differential scanning calorimeter measures a change in enthalpy with a change in time, dH/dt, as a function of programmed temperature T.
  • the glass transition phenomenon in polymers is described in Polymer Handbook, Third Edition (eds. J. Brandrup and E. H. Immergut), (John Wiley & Sons, Inc.: 1989), which is incorporated by reference herein in its entirety.
  • film-forming as used herein is meant that the anionic polymer is capable of forming a film when spread onto glass and allowed to dry at ambient temperature. Preferably, the anionic polymer is capable of forming a continuous film when dried on the glass.
  • the anionic film-forming polymer may be selected from anionic film-forming polymers that have a negative charge density of at least one negative charge per every two repeating units of polymer, preferably one negative charge per each one repeating unit of polymer.
  • Anionic film-forming polymers useful herein include sodium polystyrene sulfonate, sodium silicone t-butyl acrylate, sodium poly(styrene sulfonate/maleic anhydride), sodium poly(styrene sulfonate co acrylein), polyvinylsulfonate, polyvinyl sulfate, polyphosphate, polymethacrylate, sodium dextran sulphate, poly(ethylene oxide co styrene sulfonate), and mixtures thereof.
  • a preferred anionic, film-forming polymer for use herein is sodium polystyrene sulfonate.
  • hydrophobically modified is meant that hydrophobic regions are attached off the main chain of the polymer in order to make the polymer net more hydrophobic. Such modification is within the skill of one in the art.
  • polyampholytes is meant that the polymer contains both ionic groups off the main chain as well as surfactant-like groups off the main chain.
  • a polyampholyte useful herein is ⁇ oly(acrylamide-co-styrene sulfonate).
  • anionic film-forming polymers having a Tg of from 25°C to about 300°C, more preferably from about 50°C to about 200°C.
  • anionic film-forming polymers useful herein mclude the FLEXAN and VERSAFLEX series of sodium polystyrene sulfonates available from National Starch.
  • compositions of the present invention include from about 0.1% to about 70%, preferably from about 0.5% to about 60%, more preferably from about 1% to about 50%, even more preferably from about 2% to about 40%, by weight of the composition, of an adhesive elastomeric polymer having a Tg value of less than 40°C.
  • the polymer has an elastic modulus such that the copolymer exhibits a resistance to deformation and has limited extensibility and retraction.
  • the polymer generally may be stretched to at least 30% of the original length and return to approximately the original length when released.
  • adheres to the surface Preferably, upon drying the polymer adheres to the skin and/or hair. Preferably, the polymer forms films or welds on the skin.
  • the adhesive elastomeric polymer has a Tg of from about -200°C to less than 40°C, more preferably from about -150°C to about 10°C.
  • Suitable adhesive elastomeric polymers for use herein include oil soluble elastomers, latexes, polar solvent soluble elastomers, and mixtures thereof.
  • Suitable oil-soluble adhesive elastomeric polymers for use herein include linear copolymers, branched copolymers, random copolymers, block copolymers, di-block copolymers, tri-block copolymers, multi-block copolymers, grafted copolymers, and/or star-shaped copolymers of the following: styrene-isoprene elastomers, styrene-butadiene elastomers, styrene- ethylene/propylene-styrene elastomers, styrene-ethylene/butylene-styrene elastomers, terminal hydroxylated polyethylene/butylene elastomers, ethylene-propylene elastomers, random thermoplastic elastomers, polystyrene-co-polyethylenepropylene elastomers, and mixtures thereof.
  • grafted copolymers in the above list may also be used in the present invention.
  • grafts such as t-butyl styrene
  • Preferred are the oil-soluble adhesive elastomeric copolymers selected from styrene- isoprene linear copolymers, styrene-isoprene branched copolymers, styrene-isoprene di-block, tri- block, or star shaped copolymers, and mixtures thereof.
  • oil-soluble adhesive elastomeric polymers examples include styrene-isoprene copoloymer elastomers such as KRATON LVSI-101 and KRATON D2224P, styrene-butadiene elastomers such as KRATON D, styrene-ethylene/propylene-styrene or styrene- ethylene/butylene-styrene elastomers such as KRATON G and KRATON FG1901X, terminal hydroxylated polyethylene/butylene elastomers such as KRATON L-2203 and KRATON LI 203, all available from the Shell Oil Company.
  • styrene-isoprene copoloymer elastomers such as KRATON LVSI-101 and KRATON D2224P
  • styrene-butadiene elastomers such as KRATON D
  • oil-soluble adhesive elastomeric polymers also include branched di-block or tri-block or star-shaped copolymer elastomers of ethylene-propylene such as KRATON D1116, KRATON D1124, KRATON G1750X, KRATON G1765X, all available from the Shell Oil Company.
  • latexes useful herein include styrene-acrylate elastomer latex, silicone elastomer latex, acrylic acid ester elastomer latex, and styrene-butadiene elastomer latex.
  • styrene-acrylate elastomer latexes include those sold under the name HYSTRETCH available from B. F. Goodrich.
  • Silicone elastomer latexes useful herein include DC74166 available from Dow Corning.
  • Acrylic acid ester elastomer latexes useful herein include GELVA 2333 available from Monsanto and HYCAR available from B. F Goodrich.
  • Styrene-butadiene elastomer latexes useful herein include GOODRITE available from B. F. Goodrich.
  • Polar solvent soluble elastomers for use herein include thermoplastic block elastomers, crosslinked polyvinylalcohol, and peo-co-vinyl alcohol.
  • the topical compositions of the present invention also include from about 1% to about 99.8%, by weight of the composition, of a dermatologically acceptable carrier for the anionic film-forming polymer and the adhesive elastomeric polymer.
  • a dermatologically acceptable carrier for the anionic film-forming polymer and the adhesive elastomeric polymer.
  • the phrase "dermatologically- acceptable carrier”, as used herein, means that the carrier is suitable for topical application to the keratinous tissue, has good aesthetic properties, is compatible with the actives of the present invention and any other components, and will not cause any untoward safety or toxicity concerns.
  • the composition includes from about 20% to about 90%, more preferably from about 40% to about 90%, by weight of the composition, of the dermatologically acceptable carrier.
  • suitable dermatologically acceptable carriers for use herein include volatile organic solvents, water, polar solvents, ketones, aromatic hydrocarbons, aliphatic hydrocarbons, silicone solvents, aliphatic alcohols, diacetone alcohol, esters, alcohols, glycols, glycol ethers, aromatics.
  • a preferred carrier is water.
  • Mixtures of dermatologically acceptable carriers may be used herein. Preferred mixtures include water and alcohol; water and aliphatic hydrocarbons.
  • Examples of aliphatic hydrocarbons useful herein include isododecane, isohexadecane, and isopropylmyristate.
  • Examples of silicone solvents useful herein include cyclomethicone, dimethiconol, and dimethicone.
  • Examples of ketones useful herein include hexane/methyl ethyl ketone blends and methyl isobutyl ketone.
  • Examples of alcohols useful herein include isopropyl alcohol and those with similar properties.
  • Examples of volatile organic solvents useful herein include hydrocarbon oils, silicone oils, and mixtures thereof. A preferred volatile carrier is isododecane.
  • the carrier can be in a wide variety of forms.
  • the carrier may be a single solvent, a mixture of solvents, a propellant/solvent mixture, or the carrier may be, for example, in the form of an emulsion.
  • Emulsion carriers useful herein mclude, microemulsions, oil-in-water, water-in- silicone, water-in-oil, water-in-oil-in-water, and oil-in-water-in-silicone emulsions.
  • Preferred carriers for use herein include single solvents and mixtures of solvents.
  • Preferred emulsion carriers include water-in-silicone, water-in-oil, and microemulsions.
  • Emulsifiers may also be used in the emulsion forms of the present invention. Suitable emulsif ⁇ ers are disclosed in, for example, U.S. Patent 3,755,560, issued August 28, 1973, Dickert et al; U.S. Patent 4,421,769, issued December 20, 1983, Dixon et al.; and McCutcheon's Detergents and Emulsifiers. North American Edition, pages 317-324 (1986).
  • Water-in-silicone emulsions contain a silicone phase and a dispersed aqueous phase.
  • Silicone phase a silicone phase and a dispersed aqueous phase.
  • Preferred water-in-silicone emulsions of the present invention contain from about 0.1% to about 60%, preferably from about 1% to about 40%, by weight of the composition, of a silicone phase.
  • the silicone phase contains a polyorganosiloxane oil.
  • the silicone phase of these preferred emulsions may contain up to 50%, by weight of the silicone phase, of organopolysiloxane oil and between about 50% and about 99.9%, by weight of the silicone phase, of a non-silicone oil. Water-in-silicone emulsions of this type are described in PCT Application WO 97/21423, published June 19, 1997.
  • the organopolysiloxane oil for use in the composition may be volatile, non-volatile, or a mixture of volatile and non-volatile silicones.
  • nonvolatile refers to those silicones that are liquid under ambient conditions and have a flash point (under one atmospheric of pressure) of or greater than about 100°C.
  • volatile refers to all other silicone oils.
  • Suitable organopolysiloxanes can be selected from a wide variety of silicones spanning a broad range of volatilities and viscosities. Examples of suitable organopolysiloxane oils include polyalkylsiloxanes, cyclic polyalkylsiloxanes, and polyalkylarylsiloxanes.
  • polyalkylsiloxanes include the polydimethylsiloxanes, which are also known as dimethicones, examples of which include the Vicasil® series sold by General
  • Dimethiconols are also suitable for use in the composition.
  • Commercially available dimethiconols are typically sold as mixtures with dimethicone or cyclomethicone (e.g. Dow
  • Polyalkylaryl siloxanes are also suitable for use in the composition.
  • non-silicone oils suitable for use in the continuous silicone phase are those well known in the chemical arts in topical personal care products in the form of water-in-oil emulsions, e.g., mineral oil, vegetable oils, synthetic oils, semisynthetic oils, etc.
  • Aqueous phase e.g., mineral oil, vegetable oils, synthetic oils, semisynthetic oils, etc.
  • compositions of the present invention may, in some embodiments, contain from about 0.1% to about 90%, preferably from about 0.5% to about 50%, more preferably from about 1% to about 20%, by weight of the composition, of an aqueous phase.
  • the aqueous phase can be water, or a combination of water and one or more water soluble or dispersible ingredients.
  • suitable ingredients include thickeners, acids, bases, gums, water-soluble or dispersible alcohols and polyols, buffers, preservatives, sunscreening agents, colorings, and the like.
  • the water-in-silicone emulsions of the present invention may, in some embodiments, contain from about 0.1% to about 10%, by weight of the composition, of an emulsifier.
  • the emulsifier helps disperse and suspend the aqueous phase within the continuous silicone phase.
  • emulsifying agents can be employed herein to form the preferred water- in-silicone emulsion.
  • Known or conventional emulsifying agents can be used in the composition, provided that the selected emulsifying agent is chemically and physically compatible with components of the composition of the present invention, and provides the desired dispersion characteristics.
  • Suitable emulsifiers include silicone emulsifiers, non-silicon-containing emulsifiers, and mixtures thereof, known by those skilled in the art for use in topical personal care products.
  • Useful silicone emulsifiers include dimethicone copolyols. These materials are polydimethyl siloxanes which have been modified to include polyether side chains such as polyethylene oxide chains, polypropylene oxide chains, mixtures of these chains, and polyether chains containing moieties derived from both ethylene oxide and propylene oxide. Other examples include alkyl-modified dimethicone copolyols, i.e., compounds which contain C 2 -C 3 o pendant side chains.
  • Nonlimiting examples of dimethicone copolyols and other silicone surfactants useful as emulsifiers herein include polydimethylsiloxane polyether copolymers with pendant polyethylene oxide sidechains, polydimethylsiloxane polyether copolymers with pendant polypropylene oxide sidechains, polydimethylsiloxane polyether copolymers with pendant mixed polyethylene oxide and polypropylene oxide sidechains, polydimethylsiloxane polyether copolymers with pendant mixed poly(ethylene)(propylene)oxide sidechains, polydimethylsiloxane polyether copolymers with pendant organobetaine sidechains, polydimethylsiloxane polyether copolymers with pendant carboxylate sidechains, polydimethylsiloxane polyether copolymers with pendant quaternary ammonium sidechains; and also further modifications of the preceding copolymers containing pendant C2-C30 straight, branched, or cyclic alky
  • dimethicone copolyols useful herein sold by Dow Corning Corporation are Dow Coming® 190, 193, Q2-5220, 2501 Wax, 2-5324 fluid, and 3225C (this later material being sold as a mixture with cyclomethicone). Cetyl dimethicone copolyol is commercially available as a mixture with polyglyceryl-4 isostearate (and) hexyl laurate and is sold under the tradename ABIL® WE-09 (available from Goldschmidt).
  • Cetyl dimethicone copolyol is also commercially available as a mixture with hexyl laurate (and) polyglyceryl-3 oleate (and) cetyl dimethicone and is sold under the tradename ABIL® WS-08 (also available from Goldschmidt).
  • dimethicone copolyols also include lauryl dimethicone copolyol, dimethicone copolyol acetate, dimethicone copolyol adipate, dimethicone copolyolamine, dimethicone copolyol behenate, dimethicone copolyol butyl ether, dimethicone copolyol hydroxy stearate, dimethicone copolyol isostearate, dimethicone copolyol laurate, dimethicone copolyol methyl ether, dimethicone copolyol phosphate, and dimethicone copolyol stearate. See International Cosmetic Ingredient Dictionary. Fifth Edition, 1993.
  • Dimethicone copolyol emulsifiers useful herein are described, for example, in U.S. Patent No. 4,960,764, to Figueroa, Jr. et al., issued October 2, 1990; European Patent No. EP 330,369, to SanoGueira, published August 30, 1989; G.H. Dahms, et al., "New Formulation Possibilities Offered by Silicone Copolyols," Cosmetics & Toiletries, vol. 110, pp. 91-100, March 1995; M.E. Carlotti et al., "Optimization of W/O-S Emulsions And Study Of The Quantitative Relationships Between Ester Structure And Emulsion Properties," J. Dispersion Science And Technology.
  • emulsifiers are described, for example, in McCutcheon's, Detergents and Emulsifiers. North American Edition (1986), published by Allured Publishing Corporation.
  • oil-in-water emulsions having a continuous aqueous phase and a hydrophobic, water-insoluble phase ("oil phase") dispersed therein.
  • oil phase hydrophobic, water-insoluble phase
  • suitable oil-in-water emulsion carriers are described in U.S. Pat. No. 5,073,371, to Turner, D.J. et al., issued Dec. 17, 1991, and U.S. Pat. No. 5,073,372, to Turner, D.J. et al., issued Dec. 17, 1991.
  • the oil-in-water emulsion forms of the present invention may, in some embodiments, contain from about 0.05% to about 10%, preferably from about 1% to about 6%, and more preferably from about 1% to about 3% of a surfactant which can disperse the hydrophobic materials in the water phase (percentages by weight of the topical carrier).
  • Surfactants useful herein include nonionic, cationic, anionic, zwitterionic, and amphoteric surfactants such as are known in the art. See, e.g., McCutcheon's, Detergents and Emulsifiers. North American Edition (1986), published by Allured Publishing Corporation and incorporated herein by reference.
  • the surfactants useful herein can contain a single surfactant, or any combination of suitable surfactants. Water
  • the preferred oil-in-water emulsion contains from about 0.1% to about 99%, preferably from about 1% to about 90%, more preferably from about 5% to about 80% water, by weight of the composition.
  • compositions of the subject invention may contain a dermatologically acceptable emollient.
  • emollient refers to a material useful for the prevention or relief of dryness, as well as for the protection of the skin.
  • suitable emollients are known and may be used herein. Sagarin, Cosmetics. Science and Technology. 2nd Edition, Vol. 1, pp. 32-43 (1972), incorporated herein by reference, contains numerous examples of materials suitable as an emollient.
  • a preferred emollient is glycerin. Glycerin is preferably used in an amount of from or about 0.001 to or about 30%, more preferably from or about 0.01 to or about 20%, still more preferably from or about 0.1 to or about 10%.
  • Ointments of the present invention may contain a simple carrier base of animal or vegetable oils or semi-solid hydrocarbons (oleaginous); absorption ointment bases which absorb water to form emulsions; or water soluble carriers, e.g., a water soluble solution carrier.
  • Ointments may further contain a thickening agent, such as described in Sagarin, Cosmetics. Science and Technology, 2nd Edition, Vol. 1, pp. 72-73 (1972), incorporated herein by reference, and/or an emollient.
  • an ointment may contain from about 2% to about 10% of an emollient; from about 0.1% to about 2% of a thickening agent; and the other ingredients in the above described amounts.
  • compositions of the present invention may be formulated as a cosmetic foundation.
  • the term "foundation" refers to a liquid, semi-liquid, semi- solid, or solid skin cosmetic which includes, but is not limited to lotions, creams, gels, pastes, cakes, and the like.
  • the foundation can either be used over a large area of the skin, such as over the face, or may be applied to specific areas to hide skin imperfections and impart a smooth, even appearance to the skin.
  • Foundations of the present invention may include conventional ingredients such as oils, colorants, pigments, emollients, fragrances, stabilizers, and the like.
  • compositions of the present invention may, in some embodiments, further contain an additional stress creation material (in addition to the ionic film-forming polymer discussed above) that is useful for providing additional stress to the skin in order to further regulate the appearance of skin wrinkles and/or style hair.
  • additional stress creation material in addition to the ionic film-forming polymer discussed above
  • Preferred for use herein are inorganic colloids and oil-soluble polymers, more fully discussed below.
  • compositions of the present invention may, in some embodiments, further include from about 0.1% to about 60%, by weight of the composition, of an inorganic colloid.
  • the inorganic colloid is a film-forming inorganic colloid having a Tg of greater than 25°C.
  • film-forming as used herein is meant that the dispersed inorganic colloid is capable of forming a film when spread onto glass and allowed to dry at ambient temperature.
  • the inorganic colloid is capable of forming a continuous film when dried on the glass.
  • Preferred inorganic film-forming colloid useful herein include silica, boehmite alumina, zirconium dioxide, zirconium polyanions, boron nitride, nickel hydroxide, nickel acetate, zinc hydroxide, titanium dioxide and mixtures thereof.
  • An even more preferred inorganic film- forming colloid for use herein is silica.
  • the inorganic colloid is in the form of a sol.
  • sol as used herein is meant a dispersion of the inorganic colloid material in a polar solvent.
  • polar solvent refers to those solvents that contain hydroxyl and/or carbonyl groups and also have high dielectric constants and strong polarity.
  • the inorganic colloid is negatively charged and has a particle size of less than 50 nm and a surface area of greater than 100 m 2 /g.
  • the inorganic colloid has a Tg of from 25°C to about 1200°C, more preferably from about 50°C to about 900°C.
  • examples of such compounds include colloidal silica such as Si0 2 , commercially available as NALCO 1034A silica, NALCO 1115 silica, LUDOX, and SNOWTEX, from Nalco Chemical.
  • colloidal beohmite/alumina such as A1 2 0 3 commerically available as ALUMINA SOL 520.
  • examples also include colloidal zirconium dioxide sol Zr0 2 or polyanions like Zr(HP0 ) 2 .
  • the topical compositions of the present invention may, in some embodiments, further include from about 0.1% to about 60%, preferably from about 1% to about 50%, more preferably from about 3% to about 40%, even more preferably from about 5% to about 25%, by weight of the composition, of an oil-soluble, film-forming polymer having a Tg of greater than 25 °C.
  • the oil-soluble film-forming polymers have a Tg of from about 25°C to about 750°C, more preferably from about 50°C to about 600°C.
  • oil-soluble film-forming polymers useful herein include alkyds, shellacs, polystyrene, organosiloxane resins, and mixtures thereof.
  • Preferred oil-soluble film-forming polymers for use herein include film-forming organosiloxane resins having a Tg of greater than 25°C.
  • the organosilioxane resins contain R3SiO ⁇ / 2 "M” units, R 2 SiO "D” units, RSi0 / 2 "T” units, and/or Si0 2 "Q” units.
  • the "M", “D", “T”, and/or "Q” units are selected to satisfy the relationship n SiO(4_ n )/2 where n is a value between 1.0 and 1.50 and R is a to C ⁇ 2 lower alkyl group.
  • R is a methyl group.
  • a small amount, up to 5%, of silanol or alkoxy functionality may also be present in the resin structure as a result of processing.
  • the resin is soluble in organic solvents such as toluene, xylene, isoparaffins, and cyclosiloxanes or the volatile carrier, indicating that the resin is not tightly crosslinked.
  • organic solvents such as toluene, xylene, isoparaffins, and cyclosiloxanes or the volatile carrier, indicating that the resin is not tightly crosslinked.
  • Particularly preferred are resins comprising repeating rnonofunctional or R3SiO ⁇ /2 "M" units and the quadrafunctional or Si0 2 "Q" units, otherwise known as "MQ" resins.
  • organosiloxane resins useful herein include Wacker MQ (Wacker-Belsil TMS) and WACKER MT resins available from Wacker Silicones Corporation of Adrian, Michigan; GE MQ (including GE SRI 000 and SS4267) from the General Electric Company; and DOW CORNING MQ, (DC593) available from Dow Corning.
  • a preferred oil-soluble film-forming polymer for use herein is poly(trimethylsiloxy silicate) .
  • compositions of the present invention may, in some embodiments, contain one or more additional skin care actives.
  • the additional components should be suitable for application to keratinous tissue, that is, when incorporated into the composition they are suitable for use in contact with human keratinous tissue without undue toxicity, incompatibility, instability, allergic response, and the like within the scope of sound medical judgment.
  • CTFA Cosmetic Ingredient Handbook, Second Edition (1992) describes a wide variety of nonlimiting cosmetic and pharmaceutical ingredients commonly used in the skin care industry, which are suitable for use in the compositions of the present invention. Examples of these ingredient classes include: abrasives, absorbents, aesthetic components such as fragrances, pigments, colorings/colorants, essential oils, skin sensates, astringents, etc.
  • anti-acne agents e.g., clove oil, menthol, camphor, eucalyptus oil, eugenol, menthyl lactate, witch hazel distillate
  • anti-acne agents e.g., clove oil, menthol, camphor, eucalyptus oil, eugenol, menthyl lactate, witch hazel distillate
  • antimicrobial agents e.g., iodopropyl butylcarbamate
  • antioxidants e.g., iodopropyl butylcarbamate
  • binders biological additives, buffering agents, bulking agents, chemical additives, colorants, cosmetic astringents, cosmetic biocides, denaturants, drug astringents, external analgesics, opacifying agents, pH adjusters, propellants, reducing agents, sequestrants, skin bleaching and lightening agents (e.g., hydroquinone and ascorbyl
  • ethyl panthenol ethyl panthenol
  • aloe vera pantothenic acid and its derivatives
  • allantoin bisabolol
  • dipotassium glycyrrhizinate skin treating agents
  • thickeners thickeners
  • vitamins and derivatives thereof ethyl panthenol
  • the actives useful herein can be categorized by the benefit they provide or by their postulated mode of action. However, it is to be understood that the actives useful herein can in some instances provide more than one benefit or operate via more than one mode of action. Therefore, classifications herein are made for the sake of convenience and are not intended to limit the active to that particular application or applications listed.
  • compositions of the present invention may, in some embodiments, contain a safe and effective amount of phytantriol.
  • Phytantriol is the common name for the chemical known as 3,7,1 l,15,tetramethylhexadecane-l,2,3,-triol.
  • Phytantriol is commercially available from BASF (1609 Biddle Avenue, Whyandotte, MI).
  • phytantriol is useful as a spider vessel/ red blotchiness repair agent, a dark circle/puffy eye repair agent, sallowness repair agent, a sagging repair agent, an anti-itch agent, a skin thickening agent, a pore reduction agent, oil/shine reduction agent, a post-inflammatory hype ⁇ igmentation repair agent, wound treating agent, an anti-cellulite agent, and for regulating skin texture, including wrinkles and fine lines.
  • the phytantriol When included in compositions of the present invention, the phytantriol preferably is included in an amount from about 0.001% to about 50% by weight of the composition, more preferably from about 0.01% to about 20%, even more preferably from about 0.1% to about 15%, even more preferably from about 0.2% to about 10%.
  • the topical compositions of the present invention may, in some embodiments, contain a safe and effective amount of farnesol.
  • Farnesol is a naturally occurring substance which is believed to act as a precursor and/or intermediate in the biosynthesis of squalene and sterols, especially cholesterol.
  • Farnesol is also involved in protein modification and regulation (e.g., farnesylation of proteins), and there is a cell nuclear receptor which is responsive to farnesol.
  • farnesol is [2E,6E]-3,7,ll-trimethyl-2,6,10-dodecatrien-l-ol and as used herein "farnesol” includes isomers and tautomers of such.
  • Farnesol is commercially available, e.g., under the names farnesol (a mixture of isomers from Dragoco, 10 Gordon Drive, Totowa, New Jersey) and trans-trans-farnesol (Sigma Chemical Company, P. O. Box 14508, St. Louis, Missouri).
  • the composition preferably contains from about 0.001% to about 50%, by weight of the composition, more preferably from about 0.01% to about 20%, even more preferably from about 0.1% to about 15%, even more preferably from about 0.1% to about 10% of farnesol.
  • compositions of the present invention may further contain a safe and effective amount of one or more anti-wrinkle actives or anti-atrophy actives.
  • anti-wrinkle/anti-atrophy actives suitable for use in the compositions of the present invention include sulfur-containing D and L amino acids and their derivatives and salts, particularly the N-acetyl derivatives, a preferred example of which is N-acetyl-L-cysteine; thiols, e.g.
  • ethane thiol hydroxy acids (e.g., alpha- hydroxy acids such as lactic acid and glycolic acid or beta-hydroxy acids such as salicylic acid and salicylic acid derivatives such as the octanoyl derivative), phytic acid, lipoic acid; lysophosphatidic acid, skin peel agents (e.g., phenol and the like), vitamin B 3 compounds and retinoids which enhance the keratinous tissue appearance benefits of the present invention, especially in regulating keratinous tissue condition, e.g., skin condition.
  • compositions of the present invention may contain a safe and effective amount of a vitamin B3 compound.
  • Vitamin B 3 compounds are particularly useful for regulating skin condition as described in U. S. Patent No. 5,939,082 issued August 17, 1999, and inco ⁇ orated herein by reference.
  • the compositions preferably contain from about 0.01% to about 50%, more preferably from about 0.1% to about 10%, even more preferably from about 0.5% to about 10%, and still more preferably from about 1% to about 5%, by weight of the composition, of the vitamin B3 compound.
  • vitamin B3 compound means a compound having the formula:
  • R is - CONH 2 (i.e., niacinamide), - COOH (i.e., nicotinic acid) or - CH OH (i.e., nicotinyl alcohol); derivatives thereof; and salts of any of the foregoing.
  • CONH 2 i.e., niacinamide
  • COOH i.e., nicotinic acid
  • CH OH i.e., nicotinyl alcohol
  • Exemplary derivatives of the foregoing vitamin B3 compounds include nicotinic acid esters, including non-vasodilating esters of nicotinic acid (e.g., tocopheryl nicotinate), nicotinyl amino acids, nicotinyl alcohol esters of carboxylic acids, nicotinic acid N-oxide and niacinamide N-oxide.
  • nicotinic acid esters including non-vasodilating esters of nicotinic acid (e.g., tocopheryl nicotinate), nicotinyl amino acids, nicotinyl alcohol esters of carboxylic acids, nicotinic acid N-oxide and niacinamide N-oxide.
  • vitamin B3 compounds are well known in the art and are commercially available from a number of sources, e.g., the Sigma Chemical Company (St. Louis, MO); ICN Biomedicals, Inc. (Irvin, CA) and Aldrich Chemical Company (Milwaukee, WI).
  • the vitamin compounds may be included as the substantially pure material, or as an extract obtained by suitable physical and/or chemical isolation from natural (e.g., plant) sources.
  • the compositions of the present invention may also contain a retinoid.
  • retinoid includes all natural and/or synthetic analogs of Vitamin A or retinol-like compounds which possess the biological activity of Vitamin A in the skin as well as the geometric isomers and stereoisomers of these compounds.
  • the retinoid is preferably retinol, retinol esters (e.g., C -
  • C 22 alkyl esters of retinol including retinyl palmitate, retinyl acetate, retinyl propionate), retinal, and/or retinoic acid (including all-trans retinoic acid and/or 13-cis-retinoic acid), more preferably retinoids other than retinoic acid.
  • retinol including retinyl palmitate, retinyl acetate, retinyl propionate
  • retinal and/or retinoic acid (including all-trans retinoic acid and/or 13-cis-retinoic acid), more preferably retinoids other than retinoic acid.
  • retinoic acid including all-trans retinoic acid and/or 13-cis-retinoic acid
  • retinoids other than retinoic acid are well known in the art and are commercially available from a number of sources, e.g., Sigma Chemical Company (St. Louis, MO), and Boerhinger Mann
  • Suitable retinoids are tocopheryl-retinoate [tocopherol ester of retinoic acid (trans- or cis-), adapalene ⁇ 6-[3-(l-adamantyl)-4-methoxyphenyl]-2-naphthoic acid ⁇ , and tazarotene (ethyl 6-[2- (4,4-dimethylthiochroman-6-yl)-ethynyl]nicotinate).
  • Preferred retinoids are retinol, retinyl palmitate, retinyl acetate, retinyl propionate, retinal and combinations thereof.
  • the retinoid may be included as the substantially pure material, or as an extract obtained by suitable physical and/or chemical isolation from natural (e.g., plant) sources.
  • the retinoid is preferably substantially pure, more preferably essentially pure.
  • compositions of this invention may contain a safe and effective amount of the retinoid, such that the resultant composition is safe and effective for regulating keratinous tissue condition, preferably for regulating visible and/or tactile discontinuities in skin, more preferably for regulating signs of skin aging, even more preferably for regulating visible and/or tactile discontinuities in skin texture associated with skin aging.
  • the compositions preferably contain from or about 0.005% to or about 2%, more preferably 0.01% to or about 2%, retinoid.
  • Retinol is preferably used in an amount of from or about 0.01% to or about 0.15%; retinol esters are preferably used in an amount of from or about 0.01% to or about 2% (e.g., about 1%); retinoic acids are preferably used in an amount of from or about 0.01% to or about 0.25%; tocopheryl- retinoate, adapalene, and tazarotene are preferably used in an amount of from or about 0.01% to or about 2%.
  • compositions of the present invention contain both a retinoid and a Vitamin B3 compound
  • the retinoid is preferably used in the above amounts
  • the vitamin B3 compound is preferably used in an amount of from or about 0.1% to or about 10%, more preferably from or about 2% to or about 5%.
  • Peptides including but not limited to, di-, tri-, tetra-, and pentapeptides and derivatives thereof, may be included in the compositions of the present invention in amounts that are safe and effective.
  • peptides refers to both the naturally occurring peptides and synthesized peptides. Also useful herein are naturally occurring and commercially available compositions that contain peptides.
  • Suitable dipeptides for use herein include Carnosine® (beta-ala-his).
  • Suitable tripeptides for use herein include, gly-his-lys, arg-lys-arg, his-gly-gly.
  • Preferred tripeptides and derivatives thereof include palmitoyl-gly-his-lys, which may be purchased as Biopeptide CL® (lOOppm of palmitoyl-gly-his-lys commercially available from Sederma, France); Peptide CK (arg-lys-arg); PEPTIDE CK+ (ac-arg-lys-arg-NH 2 ); and a copper derivative of his-gly-gly sold commercially as
  • IAMIN from Sigma (StLouis, Missouri). Tetrapeptides and pentapeptides are also suitable for use herein.
  • a preferred commercially available pentapeptide derivative composition is MATRIXYL®, (commercially available from Sederma France).
  • peptides are preferably included in amounts of from about lxl0 "6 % to about 10%, more preferably from about lxl0 "6 % to about 0.1%, even more preferably from about lxl0 "5 % to about 0.01%, by weight of the composition.
  • the compositions preferably contain from about 0.1% to about 5%, by weight of the composition, of such peptides.
  • compositions preferably contain from about 0.1% to about 10%, by weight compositions, of Matrixyl® and/or Biopeptide CL® peptide-containing compositions.
  • compositions of the present invention may include a safe and effective amount of an anti-oxidant/radical scavenger.
  • the anti-oxidant/radical scavenger is especially useful for providing protection against UV radiation which can cause increased scaling or texture changes in the stratum comeum and against other environmental agents which can cause skin damage.
  • a safe and effective amount of an anti-oxidant/radical scavenger may be added to the compositions of the subject invention, preferably from about 0.1% to about 10%, more preferably from about 1% to about 5%, of the composition.
  • Anti-oxidants/radical scavengers such as ascorbyl esters of fatty acids, tocopherol (vitamin E), tocopherol sorbate, tocopherol acetate, other esters of tocopherol, amines (e.g., N,N- diethylhydroxylamine, amino-guanidine), sulfhydryl compounds (e.g., glutathione), lycine pidolate, arginine pilolate, nordihydroguaiaretic acid, bioflavonoids, curcumin, lysine, methionine, proline, superoxide dismutase, silymarin, tea extracts, grape skin/seed extracts, melanin, and rosemary extracts may be used.
  • amines e.g., N,N- diethylhydroxylamine, amino-guanidine
  • sulfhydryl compounds e.g., glutathione
  • lycine pidolate argin
  • Preferred anti-oxidants/radical scavengers are selected from tocopherol sorbate and other esters of tocopherol, more preferably tocopherol sorbate.
  • tocopherol sorbate in topical compositions and applicable to the present invention is described in U.S. Patent No. 4,847,071, issued on July 11, 1989 to Donald L. Bissett, Rodney D. Bush and Ranjit Chatterjee.
  • compositions of the present invention may optionally contain a flavonoid compound.
  • Flavonoids are broadly disclosed in U.S. Patents 5,686,082 and 5,686,367, both of which are herein inco ⁇ orated by reference.
  • Flavonoids suitable for use in the present invention are flavanones selected from unsubstituted flavanones, mono-substituted flavanones, and mixtures thereof; chalcones selected from unsubstituted chalcones, mono-substituted chalcones, di- substituted chalcones, tri-substituted chalcones, and mixtures thereof; flavones selected from unsubstituted flavones, mono-substituted flavones, di-substituted flavones, and mixtures thereof; one or more isoflavones; coumarins selected from unsubstituted coumarins, mono-substituted coumarins, di-sub
  • substituted means flavonoids wherein one or more hydrogen atom of the flavonoid has been independently replaced with hydroxyl, C1-C8 alkyl, C1-C4 alkoxyl, O-glycoside, and the like or a mixture of these substituents.
  • suitable flavonoids include, but are not limited to, unsubstituted flavanone, mono-hydroxy flavanones (e.g., 2'-hydroxy flavanone, 6-hydroxy flavanone, 7-hydroxy
  • dihydroxy isoflavone dihydroxy isoflavone
  • 5,7-dihydroxy-4'-methoxy isoflavone soy isoflavones (a mixture extracted from soy)
  • unsubstituted coumarin 4-hydroxy coumarin, 7-hydroxy coumarin, 6-hydroxy-4- methyl coumarin, unsubstituted chromone, 3-formyl chromone, 3-formyl-6-isopropyl chromone, unsubstituted dicoumarol, unsubstituted chromanone, unsubstituted chromanol, and mixtures thereof.
  • Flavonoid compounds useful herein are commercially available from a number of sources, e.g., Indofine Chemical Company, Inc. (Somerville, New Jersey), Steraloids, Inc. (Wilton, New Hampshire), and Aldrich Chemical Company, Inc. (Milwaukee, Wisconsin).
  • the herein described flavonoid compounds are preferably present in the instant invention at concentrations of from about 0.01% to about 20%, more preferably from about 0.1% to about 10%, and still more preferably from about 0.5% to about 5%.
  • a safe and effective amount of an anti-inflammatory agent may be added to the compositions of the present invention, preferably from about 0.1% to about 10%, more preferably from about 0.5% to about 5%, of the composition.
  • the anti-inflammatory agent enhances the skin appearance benefits of the present invention, e.g., such agents contribute to a more uniform and acceptable skin tone or color.
  • the exact amount of anti-inflammatory agent to be used in the compositions will depend on the particular anti-inflammatory agent utilized since such agents vary widely in potency.
  • Steroidal anti-inflammatory agents including but not limited to, corticosteroids such as hydrocortisone, hydroxyltriamcinolone, alpha-methyl dexamethasone, dexamethasone-phosphate, beclomethasone dipropionates, clobetasol valerate, desonide, desoxymethasone, desoxycorticosterone acetate, dexamethasone, dichlorisone, diflorasone diacetate, diflucortolone valerate, fluadrenolone, fluclorolone acetonide, fludrocortisone, flumethasone pivalate, fluosinolone acetonide, fluocinonide, flucortine butylesters, fluocortolone, fluprednidene (fluprednylidene) acetate, flurandrenolone, halcinonide, hydrocortisone acetate, hydrocortisone butyrate, methyl
  • a second class of anti-inflammatory agents which is useful in the compositions includes the nonsteroidal anti-inflammatory agents.
  • the variety of compounds encompassed by this group are well-known to those skilled in the art.
  • compositions include, but are not limited to:
  • the oxicams such as piroxicam, isoxicam, tenoxicam, sudoxicam, and CP- 14,304;
  • salicylates such as aspirin, disalcid, benorylate, trilisate, safapryn, solprin, diflunisal, and fendosal;
  • acetic acid derivatives such as diclofenac, fenclofenac, indomethacin, sulindac, tolmetin, isoxepac, furofenac, tiopinac, zidometacin, acematacin, fentiazac, zomepirac, clindanac, oxepinac, felbinac, and ketorolac;
  • the fenamates such as mefenamic, meclofenamic, flufenamic, niflumic, and tolfenamic acids;
  • the propionic acid derivatives such as ibuprofen, naproxen, benoxaprofen, flurbiprofen, ketoprofen, fenoprofen, fenbufen, indopropfen, pi ⁇ rofen, ca ⁇ rofen, oxaprozin, pranoprofen, miroprofen, tioxaprofen, suprofen, alminoprofen, and tiaprofenic; and
  • the pyrazoles such as phenylbutazone, oxyphenbutazone, feprazone, azapropazone, and trimethazone.
  • non-steroidal anti-inflammatory agents may also be employed, as well as the dermatologically acceptable esters of these agents.
  • etofenamate a flufenamic acid derivative
  • ibuprofen, naproxen, flufenamic acid, etofenamate, aspirin, mefenamic acid, meclofenamic acid, piroxicam and felbinac are preferred; ibuprofen, naproxen, ketoprofen, etofenamate, aspirin and flufenamic acid are more preferred.
  • so-called "natural" anti-inflammatory agents are useful in methods of the present invention.
  • Such agents may suitably be obtained as an extract by suitable physical and/or chemical isolation from natural sources (e.g., plants, fungi, by-products of microorganisms) or can be synthetically prepared.
  • natural sources e.g., plants, fungi, by-products of microorganisms
  • kola extract, chamomile, red clover extract, and sea whip extract may be used.
  • Additional anti-inflammatory agents useful herein include compounds of the Licorice (the plant genus/species Glvcyrrhiza glabra family, including glycyrrhetic acid, glycyrrhizic acid, and derivatives thereof (e.g. esters).
  • Suitable esters include C - C 2 4 saturated or unsaturated esters of the acids, preferably C ⁇ Q - C 2 4, more preferably Gi g - C 2 4-
  • Specific examples of the foregoing include oil soluble licorice extract, the glycyrrhizic and glycyrrhetic acids themselves.
  • compositions of the present invention may also contain a safe and effective amount of an anti-cellulite agent.
  • Suitable agents may include, but are not limited to, xanthine compounds (e.g., caffeine, theophylline, theobromine, and aminophylline).
  • compositions of the present invention may also contain a safe and effective amount of a topical anesthetic.
  • topical anesthetic drugs include benzocaine, lidocaine, bupivacaine, chlo ⁇ rocaine, dibucaine, etidocaine, mepivacaine, tetracaine, dyclonine, hexylcaine, procaine, cocaine, ketamine, pramoxine, phenol, and pharmaceutically acceptable salts thereof.
  • compositions of the present invention may comprise a skin soothing or skin healing active.
  • Skin soothing or skin healing actives suitable for use herein include panthenoic acid derivatives (including panthenol, dexpanthenol, ethyl panthenol), aloe vera, allantoin, bisabolol, and dipotassium glycyrrhizinate.
  • a safe and effective amount of a skin soothing or skin healing active may be added to the present composition, preferably, from about 0.1% to about 30%, more preferably from about 0.5% to about 20%, still more preferably from about 0.5% to about 10 %, by weight of the composition formed. a) bisabolol
  • compositions of the present invention may also contain a safe and effective amount of bisabolol.
  • Bisabolol is a naturally occurring unsaturated monocyclic te ⁇ ene alcohol having the following structure
  • Bisabolol can be synthetic (d,l - alpha-isomer or (+/-)-alpha-isomer) or natural ((-)-alpha-isomer) in origin and can be used as essentially pure compounds or mixtures of compounds (e.g., extracts from natural sources such as chamomile).
  • the alpha form of bisabolol (a-bisabolol) is used in a variety of cosmetic products as a skin conditioning or soothing agent.
  • bisabolol includes chamomile extract or oil and any isomers and tautomers of such.
  • Suitable bisabolol compounds are commercially available as a natural material from Dragoco (Totowa, New Jersey) under the product name alpha- bisabolol natural and as a synthetic material from Fluka (Milwaukee, Wisconsin) under the product name alpha-bisabolol.
  • the composition preferably contains from about 0.001% to about 50%, by weight of the composition, more preferably from about 0.01% to about 20%, of bisabolol, even more preferably from about 0.1% to about 5%.
  • compositions of the present invention may contain an antimicrobial or antifungal active.
  • Such actives are capable of destroying microbes, preventing the development of microbes or preventing the pathogenic action of microbes.
  • a safe and effective amount of an antimicrobial or antifungal active may be added to the present compositions, preferably, from about 0.001% to about 10%, more preferably from about 0.01% to about 5%, and still more preferably from about 0.05% to about 2%.
  • actives useful herein include those selected from salicylic acid, benzoyl peroxide, 3-hydroxy benzoic acid, glycolic acid, lactic acid, 4-hydroxy benzoic acid, acetyl salicylic acid, 2-hydroxybutanoic acid, 2-hydroxypentanoic acid, 2-hydroxyhexanoic acid, cis-retinoic acid, trans-retinoic acid, retinol, phytic acid, N-acetyl-L-cysteine, lipoic acid, azelaic acid, arachidonic acid, benzoylperoxide, tetracycline, ibuprofen, naproxen, hydrocortisone, acetominophen, resorcinol, phenoxyethanol, phenoxypropanol, phenoxyisopropanol, 2,4,4'- trichloro-2'-hydroxy diphenyl ether, 3,4,4'-trichlorocarbanilide, octopirox, lid
  • compositions of the subject invention may optionally contain a sunscreen active.
  • sunscreen active includes both sunscreen agents and physical sunblocks. Suitable sunscreen actives may be organic or inorganic.
  • Inorganic sunscreens useful herein include the following metallic oxides; titanium dioxide having an average primary particle size of from about 15 nm to about 100 nm, zinc oxide having an average primary particle size of from about 15 nm to about 150 nm, zirconium oxide having an average primary particle size of from about 15 n to about 150 nm, iron oxide having an average primary particle size of from about 15 nm to about 500nm, and mixtures thereof.
  • the inorganic sunscreens are present in the amount of from about 0.1% to about 20%, preferably from about 0.5% to about 10%, more preferably from about 1% to about 5%, by weight of the composition.
  • sunscreen actives include, for example: p- aminobenzoic acid, its salts and its derivatives (ethyl, isobutyl, glyceryl esters; p- dimethylaminobenzoic acid); anthranilates (i.e., o-amino-benzoates; methyl, menthyl, phenyl, benzyl, phenylethyl, linalyl, te ⁇ inyl, and cyclohexenyl esters); salicylates (amyl, phenyl, octyl, benzyl, menthyl, glyceryl, and di-pro-pyleneglycol esters); cinnamic acid derivatives (menthyl and
  • 2-ethylhexyl-p-methoxycinnamate commercially available as PARSOL MCX
  • 4,4'-t-butyl methoxydibenzoyl-methane commercially available as PARSOL 1789
  • 2-hydroxy-4- methoxybenzophenone octyldimethyl-p-aminobenzoic acid, digalloyltrioleate, 2,2-dihydroxy-4- methoxybenzophenone, ethyl-4-(bis(hydroxy-propyl))aminobenzoate
  • 2-ethylhexyl-salicylate glyceryl-p-aminobenzoate, 3,3,5-tri- methylcyclohexylsalicylate, methylanthranilate, p-dimethyl-aminobenzoic acid or aminobenzoate
  • More preferred organic sunscreen actives useful in the compositions useful in the subject invention are 2-ethylhexyl-p-methoxycinnamate, butylmethoxydibenzoyl-methane, 2-hydroxy-4- methoxybenzo-phenone, 2-phenylbenzimidazole-5-sulfonic acid, octyldimethyl-p-aminobenzoic acid, octocrylene and mixtures thereof.
  • sunscreen actives such as those disclosed in U.S. Patent No. 4,937,370 issued to Sabatelli on June 26, 1990, and U.S. Patent No. 4,999,186 issued to Sabatelli & Spimak on March 12, 1991.
  • the sunscreening agents disclosed therein have, in a single molecule, two distinct chromophore moieties which exhibit different ultra-violet radiation abso ⁇ tion spectra.
  • One of the chromophore moieties absorbs predominantly in the UVB radiation range and the other absorbs strongly in the UVA radiation range.
  • Preferred members of this class of sunscreening agents are 4-N,N-(2-ethylhexyl)methyl- aminobenzoic acid ester of 2,4-dihydroxybenzophenone; N,N-di-(2-ethylhexyl)-4-aminobenzoic acid ester with 4-hydroxydibenzoylmethane; 4-N,N-(2-ethylhexyl)methyl-aminobenzoic acid ester with 4-hydroxydibenzoylmethane; 4-N,N-(2-ethylhexyl)methyl-aminobenzoic acid ester of 2-hydroxy-4-(2-hydroxyethoxy)benzophenone; 4-N,N-(2-ethylhexyl)-methylaminobenzoic acid ester of 4-(2-hydroxyethoxy)dibenzoylmethane; N,N-di-(2-ethylhexyl)-4-aminobenzoic acid ester of 2-hydroxy-4-
  • sunscreen actives include 4,4'-t-butylmethoxydibenzoylmethane, 2- ethylhexyl-p-methoxycinnamate, phenyl benzimidazole sulfonic acid, and octocrylene.
  • a safe and effective amount of the organic sunscreen active is used, typically from about 1% to about 20%, more typically from about 2% to about 10% by weight of the composition. Exact amounts will vary depending upon the sunscreen or sunscreens chosen and the desired Sun Protection Factor (SPF).
  • SPF Sun Protection Factor
  • the personal care compositions herein may include a safe and effective amount of a hardener or softener element.
  • hardener/softener materials include poly(t-butyl styrene), poly(t-butyl styrene co-styrene), and mixtures thereof.
  • compositions of the present invention may, in some embodiments, contain a particulate material, preferably a metallic oxide. These particulates can be coated or uncoated, charged or uncharged. Charged particulate materials are disclosed in U.S. Patent No. 5,997,887, to Ha, et al., inco ⁇ orated herein by reference.
  • Particulate materials useful herein include; bismuth oxychloride, iron oxide, mica, mica treated with barium sulfate and Ti02, silica, nylon, polyethylene, talc, styrene, polypropylene, ethylene/acrylic acid copolymer, sericite, aluminum oxide, silicone resin, barium sulfate, calcium carbonate, cellulose acetate, polymethyl methacrylate, and mixtures thereof.
  • compositions of the present invention may contain a conditioning agent selected from humectants, moisturizers, or skin conditioners.
  • a conditioning agent selected from humectants, moisturizers, or skin conditioners.
  • humectants selected from humectants, moisturizers, or skin conditioners.
  • a variety of these materials can be employed and each can be present at a level of from about 0.01% to about 20%, more preferably from about 0.1% to about 10.
  • aloe vera in any of its variety of forms (e.g., aloe vera gel); polyhydroxy alcohols such as sorbitol, mannitol, xylitol, erythritol, glycerol, hexanetriol, butanetriol, propylene glycol, butylene glycol, hexylene glycol and the like; polyethylene glycols; sugars (e.g., melibiose) and starches; sugar and starch derivatives (e.g., alkoxylated glucose, fructose, glucosamine); hyaluronic acid; lactamide monoethanolamine; acetamide monoethanolamine; panthenol; allantoin; and mixtures thereof. Also useful herein are the propoxylated
  • esters are derived from a sugar or polyol moiety and one or more carboxylic acid moieties.
  • ester materials are further described in, U. S. Patent No. 2,831,854, U. S. Patent No. 4,005,196, to Jandacek, issued January 25, 1977; U. S. Patent No. 4,005,195, to Jandacek, issued January 25, 1977, U. S. Patent No. 5,306,516, to Letton et al, issued April 26, 1994; U. S. Patent No. 5,306,515, to Letton et al, issued April 26, 1994; U. S. Patent No.
  • the conditioning agent is selected from urea, guanidine, sucrose polyester, panthenol, dexpanthenol, allantoin, and combinations thereof.
  • compositions of the present invention can contain one or more thickening agents, for example clays, gums, polymeric thickeners.
  • the compositions preferably provide from about 0.1% to about 5%, more preferably from about 0.1% to about 4%, and still more preferably from about 0.25% to about 3%, by weight of the composition of the thickening agent.
  • compositions useful for the methods of the present invention are generally prepared by conventional methods such as are known in the art of making topical compositions. Such methods typically involve mixing of the ingredients in one or more steps to a relatively uniform state, with or without heating, cooling, application of vacuum, and the like.
  • compositions of the present invention may be formulated as a facial skin cosmetic, eye cosmetic, lip cosmetic, scalp hair styling aid, facial hair styling aid, moisturizer, wrinkle soothing serum, lotion, mascara, spa product, body firming cream, cellulite reducing cream, skin facial mask, skin lotion, skin cream, skin gel, eye gel, eye cream, lip gel, lip cream, cosmetic, foundation, or any other commonly known skin product or treatment.
  • a multiple-step regimen may also be employed. For example, an adhesive elastomeric polymer basecoat may be applied and then the anionic film-forming polymer in solution be applied either in combination with the basecoat application or after a brief drying period. Additionally, a dual-barrel or dual-pipette system may be implemented in which the anionic film- forming polymer is applied from one barrel and the adhesive elastomeric polymer is applied from another barrel.
  • compositions of the present invention are useful for modifying the appearance of skin and hair. Modifying the appearance of hair includes styling scalp hair, eyelashes, eyebrows, beard and/or moustache.
  • a preferred use of the compositions of the present invention is the curling of eyelashes by application of the compositions herein with a suitable implement e.g., a eyelash wand, or with the fingers.
  • Modifying the appearance of skin includes reducing the appearance of fine lines and/or wrinkles on the skin, reducing the appearance of eye bags and dark circles under the eys, sagging skin, scars/marks, dimples, pores, stretch marks, roughness, skin surface blemishes, frown lines, expression lines, rhytides, blemishes, photodamage, crevices, and/or unevenness.
  • the modification of the appearance of skin and/or hair may be enhanced by the addition of a skin or hair active.
  • skin care actives that may be added to compositions of the present invention include vitamin B3 compounds (e.g. niaicinamide), panthenol and panthenoic acid, vitamin E compounds (e.g. tocopherol acetate), and retinoids (e.g. retinyl propionate).
  • Vitamin B3 compounds e.g. niaicinamide
  • panthenol and panthenoic acid e.g. tocopherol acetate
  • retinoids e.g. retinyl propionate
  • such regulating methods are directed to thickening keratinous tissue (i.e., building the epidermis and/or dermis layers of the skin and where applicable the keratinous layers of the nail and hair shaft) and preventing and/or retarding atrophy of mammalian skin, preventing and/or retarding the appearance of spider vessels and/or red blotchiness on mammalian skin, preventing and or retarding the appearance of dark circles under the eye of a mammal, preventing and/or retarding sallowness of mammalian skin, preventing and/or retarding sagging of mammalian skin, softening and/or smoothing lips, hair and nails of a mammal, preventing and/or relieving itch of mammalian skin, regulating skin texture (e.g. wrinkles and fine lines), and improving skin color (e.g. redness, freckles).
  • keratinous tissue i.e., building the epidermis and/or dermis layers of the skin and where applicable the
  • the composition further includes a chronic active, such as niacinamide, and the composition is chronically applied to the skin.
  • a chronic active such as niacinamide
  • chronic topical application is meant continued topical application of the composition over an extended period during the subject's lifetime, preferably for a period of at least about one week, more preferably for a period of at least about one month, even more preferably for at least about three months, even more preferably for at least about six months, and more preferably still for at least about one year. While benefits are obtainable after various maximum periods of use (e.g., five, ten or twenty years), it is preferred that chronic application continue throughout the subject's lifetime. Typically applications would be on the order of about once per day over such extended periods, however application rates can vary from about once per week up to about three times per day or more.
  • compositions of the present invention can be employed to provide a skin appearance and/or feel benefit.
  • Quantities of the present compositions which are typically applied per application are, in mg composition/cm ⁇ skin, from about 0.1 mg/cm ⁇ to about 100 mg/cm ⁇ .
  • a particularly useful application amount is about 1 mg/cm ⁇ to about 10 mg/cnA
  • Modifying and/or regulating skin appearance, feel, and/or condition is preferably practiced by applying a composition in the form of a skin lotion, cream, gel, foam, ointment, paste, emulsion, spray, conditioner, tonic, cosmetic, lipstick, foundation, nail polish, after-shave, or the like which is preferably intended to be left on the skin or other keratin structure for some esthetic, prophylactic, therapeutic or other benefit (i.e., a "leave-on" composition).
  • composition After applying the composition to the skin, it is preferably left on the skin for a period of at least about 15 minutes, more preferably at least about 30 minutes, even more preferably at least about 1 hour, still more preferably for at least several hours, e.g., 12 hours.
  • Any part of the external portion of the face, hair, and/or nails can be treated, e.g., face, lips, under-eye area, eyelids, scalp, neck, torso, arms, hands, legs, feet, fingernails, toenails, scalp hair, eyelashes, eyebrows, etc.
  • the composition can be applied with the fingers or with an implement or device (e.g., pad, cotton ball, applicator pen, spray applicator, and the like).
  • the composition after drying on the skin or hair, may be "refreshed" or "touched up” by directly applying additional amounts of the composition to the areas in need of treatment.
  • Another approach to ensure a continuous exposure of the skin to at least a minimum level of the composition is to apply the compound by use of a patch applied, e.g., to the face.
  • a patch applied e.g., to the face.
  • the patch can be occlusive, semi-occlusive or non-occlusive and can be adhesive or non-adhesive.
  • the composition can be contained within the patch or be applied to the skin prior to application of the patch.
  • the patch can also include additional actives such as chemical initiators for exothermic reactions such as those described in U.S.
  • the patch is preferably left on the skin for a period of at least about 5 minutes, more preferably at least about 15 minutes, more preferably still at least about 30 minutes, even more preferably at least about 1 hour, still more preferably at night as a form of night therapy.
  • composition according to the invention can be packaged in its own bottle. It can also be packaged in two separate receptacles, each receptacle containing either the anionic film- forming polymer or the adhesive elastomeric polymer.
  • the separate receptacles may provide ease in application or product formulation.
  • the separate receptacles may also allow the consumer to control the level of physical stress on the skin (and resulting wrinkle-reduction benefit) achieved by a particular application. Examples
  • Hystreteh 43 a 50wt% aqueous latex.
  • oil soluble ingredients are pre-dissolved (e.g. Kraton in Permethyl) at 100-500 ⁇ m at between 25°C-45°C. 3. Then all of the predissolved oil ingredients are dispersed into the water-based ingredients with high shear mixing >1000 ⁇ m.
  • particle materials such as pigment and the aqueous latex are added with mixing at the end of the batch.
  • Hystretch 43 a 50wt% aqueous latex.
  • Vitamin E Acetate 10 Available from BASF as Vitamin E Acetate.
  • oil soluble ingredients are pre-dissolved (e.g. Kraton in Permethyl) at 100-500 ⁇ m at 25°C-45°C.
  • particle materials such as pigment and aqueous latex are added at the end of the batch.
  • Hystretch 43 a 50wt% aqueous latex.
  • oil soluble ingredients e.g. Kraton
  • Permethyl e.g. 1,3-butanediol
  • the batch is heated to 60°C-75°C and the pre-melted wax and emulsifier are added to the batch.
  • particle materials such as pigment and aqueous latex, are added at the end of the batch.
  • Vitamin E Acetate available from BASF as Vitamin E Acetate, available from Roche as DL-Panthenol No. 63915.
  • oil soluble ingredients e.g. Kraton
  • the batch is heated to 60°C-75°C and the pre-melted wax and emulsifier are added.
  • Hystretch 43 Available from B.F. Goodrich as Hystretch 43, a 50wt% aqueous latex. " Available from S.C. Johnson as Zinc Oxide Aqueous Solution.
  • the particle materials such as aqueous latex are added at the end of the batch.
  • oil soluble ingredients e.g. Styrene-isoprene Elastomer and Trimethylsiloxysilicate
  • Permethyl e.g. Styrene-isoprene Elastomer and Trimethylsiloxysilicate
  • the particle materials (such as pigments) are then added to the oil phase.
  • Hystretch 43 a 50wt% aqueous latex.
  • the particles (such as pigment powder beads and oil additives) are dispersed under moderate shear 100-500 ⁇ m.
  • composition is pressurized by adding the propellant and capping the package in order to create a self-foaming mousse. After application of the composition to the skin, an excellent, aesthetically-pleasing wrinkle-reducing effect was obtained.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Cosmetics (AREA)

Abstract

La présente invention concerne des compositions pour le soin de la peau contenant un polymère filmogène anionique et un polymère élastomère adhésif, ainsi que des procédés d'utilisation de ces compositions pour réguler l'aspect de la peau et/ou des cheveux. Ces compositions contiennent de 0,1 % environ à 70 % environ d'un polymère filmogène anionique, de 0,1 % environ à 70 % environ d'un polymère élastomère adhésif et de 1 % environ à 99,8 % environ d'un excipient dermatologiquement acceptable.
PCT/US2001/026234 2000-08-22 2001-08-22 Compositions pour soins personnels contenant un polymere filmogene anionique et un polymere elastomere adhesif WO2002015874A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001286624A AU2001286624A1 (en) 2000-08-22 2001-08-22 Personal care compositions containing anionic film-forming polymer and adhesive elastomeric polymer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64349200A 2000-08-22 2000-08-22
US09/643,492 2000-08-22

Publications (3)

Publication Number Publication Date
WO2002015874A2 true WO2002015874A2 (fr) 2002-02-28
WO2002015874A3 WO2002015874A3 (fr) 2002-08-15
WO2002015874A8 WO2002015874A8 (fr) 2003-11-13

Family

ID=24581048

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/026234 WO2002015874A2 (fr) 2000-08-22 2001-08-22 Compositions pour soins personnels contenant un polymere filmogene anionique et un polymere elastomere adhesif

Country Status (2)

Country Link
AU (1) AU2001286624A1 (fr)
WO (1) WO2002015874A2 (fr)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2834884A1 (fr) * 2002-01-18 2003-07-25 Oreal Composition cosmetique longue tenue comprenant un materiau pro-adhesif et un compose diffusant separes
WO2003061611A3 (fr) * 2002-01-18 2004-03-11 Oreal Composition cosmetique longue tenue comprenant un materiau pro-adhesif et un compose diffusant separes
US20100119470A1 (en) * 2004-01-14 2010-05-13 Shiseido Company, Ltd. Method Of Reducing The Appearance Of Wrinkles
FR2954696A1 (fr) * 2009-12-24 2011-07-01 Bcm Cosmetique Composition cosmetique de revetement des fibres keratiniques
DE102010027487A1 (de) * 2010-07-16 2012-01-19 Beiersdorf Ag Haarkonditioniermittel mit formgebenden Eigenschaften
EP1733711A4 (fr) * 2004-03-19 2012-09-26 Kao Corp Preparation cosmetique pour cil
WO2018091300A1 (fr) * 2016-11-18 2018-05-24 Unilever N.V. Composition de soin buccal pour l'élimination du biofilm buccal
EP3233052A4 (fr) * 2014-12-18 2018-09-05 L'oreal Compositions et procédés de protection solaire
CN109316359A (zh) * 2018-11-29 2019-02-12 华南理工大学 一种含有纳米纤维素纤维的高保湿面膜基布及其制备方法
FR3075016A1 (fr) * 2017-12-20 2019-06-21 L'oreal Composition cosmetique comprenant un polymere tenseur et necessaire d'application utilisant un applicateur rotatif
WO2022146700A1 (fr) * 2020-12-29 2022-07-07 L'oreal Compositions anti-imperfections et méthodes d'utilisation
FR3121600A1 (fr) * 2021-04-08 2022-10-14 L'oreal Compositions cosmétiques pour le perfectionnement de la peau et procédés d’utilisation
US20230276885A1 (en) * 2022-03-04 2023-09-07 Kiss Nail Products, Inc. Artificial eyelash extension systems having enhanced appearance

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965071A (en) * 1988-10-19 1990-10-23 The Gillette Company Wrinkle masking composition of sodium polystyrene sulfonate and process for use

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003061611A3 (fr) * 2002-01-18 2004-03-11 Oreal Composition cosmetique longue tenue comprenant un materiau pro-adhesif et un compose diffusant separes
FR2834884A1 (fr) * 2002-01-18 2003-07-25 Oreal Composition cosmetique longue tenue comprenant un materiau pro-adhesif et un compose diffusant separes
US20100119470A1 (en) * 2004-01-14 2010-05-13 Shiseido Company, Ltd. Method Of Reducing The Appearance Of Wrinkles
EP1733711A4 (fr) * 2004-03-19 2012-09-26 Kao Corp Preparation cosmetique pour cil
FR2954696A1 (fr) * 2009-12-24 2011-07-01 Bcm Cosmetique Composition cosmetique de revetement des fibres keratiniques
WO2011076673A3 (fr) * 2009-12-24 2012-02-16 Bcm Cosmetique Composition cosmétique de revêtement des fibres kératiniques
DE102010027487A1 (de) * 2010-07-16 2012-01-19 Beiersdorf Ag Haarkonditioniermittel mit formgebenden Eigenschaften
EP3233052A4 (fr) * 2014-12-18 2018-09-05 L'oreal Compositions et procédés de protection solaire
WO2018091300A1 (fr) * 2016-11-18 2018-05-24 Unilever N.V. Composition de soin buccal pour l'élimination du biofilm buccal
FR3075016A1 (fr) * 2017-12-20 2019-06-21 L'oreal Composition cosmetique comprenant un polymere tenseur et necessaire d'application utilisant un applicateur rotatif
CN109316359A (zh) * 2018-11-29 2019-02-12 华南理工大学 一种含有纳米纤维素纤维的高保湿面膜基布及其制备方法
CN109316359B (zh) * 2018-11-29 2021-05-14 华南理工大学 一种含有纳米纤维素纤维的高保湿面膜基布及其制备方法
WO2022146700A1 (fr) * 2020-12-29 2022-07-07 L'oreal Compositions anti-imperfections et méthodes d'utilisation
FR3121600A1 (fr) * 2021-04-08 2022-10-14 L'oreal Compositions cosmétiques pour le perfectionnement de la peau et procédés d’utilisation
US20230276885A1 (en) * 2022-03-04 2023-09-07 Kiss Nail Products, Inc. Artificial eyelash extension systems having enhanced appearance

Also Published As

Publication number Publication date
WO2002015874A3 (fr) 2002-08-15
AU2001286624A1 (en) 2002-03-04
WO2002015874A8 (fr) 2003-11-13

Similar Documents

Publication Publication Date Title
WO2002015873A2 (fr) Compositions pour les soins personnels contenant un polymere elastomere adhesif et un colloide inorganique
AU2001273286B2 (en) Skin care compositions containing silicone elastomers
EP2105123B1 (fr) Compositions de soins dermatologiques contenant une amine-sucre et un composé de vitamine B3
CA2370201C (fr) Compositions de soin pour la peau contenant une combinaison de principes actifs de soin pour la peau
US6444647B1 (en) Skin care compositions containing combination of skin care actives
AU727801B2 (en) Methods of regulating skin appearance with vitamin B3 compound
MXPA01010575A (es) Metodos para regular la condicion de tejido queratinoso de mamiferos.
AU2003212438A1 (en) Topical use of vitamin B6 compositions
WO2002015875A2 (fr) Compositions pour soins personnels contenant un polymere filmogene soluble dans l'huile et un polymere elastomere adhesif
WO2009052518A2 (fr) Procédés et compositions destinés à réduire l'hirsutisme se manifestant par une pilosité du visage chez les femmes
WO2002015874A2 (fr) Compositions pour soins personnels contenant un polymere filmogene anionique et un polymere elastomere adhesif
EP1171093A2 (fr) Compositions de soin pour la peau contenant une combinaison de principes actifs de soin pour la peau
WO2000062741A2 (fr) Compositions de soin pour la peau contenant une combinaison de principes actifs de soin pour la peau
WO2000062745A2 (fr) Compositions de soin pour la peau contenant une combinaison de principes actifs de soin pour la peau

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EC EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 09/2002 DUE TO A TECHNICAL PROBLEM AT THE TIME OF INTERNATIONAL PUBLICATION, SOME INFORMATION WAS MISSING (81). THE MISSING INFORMATION NOW APPEARS IN THE CORRECTED VERSION.

Free format text: IN PCT GAZETTE 09/2002 DUE TO A TECHNICAL PROBLEM AT THE TIME OF INTERNATIONAL PUBLICATION, SOME INFORMATION WAS MISSING (81). THE MISSING INFORMATION NOW APPEARS IN THE CORRECTED VERSION.

NENP Non-entry into the national phase

Ref country code: JP